TRX-0237 mesylate

CAS No.	1236208-20-0	Cat. No.	BCP16840
Name	TRX-0237 mesylate
Synonyms	Leucomethylene blue Mesylate； TRX-0237; TRX 0237; TRX0237; LMTX;L-MTx; LMT-X; Leuco-MTx; Methylene blue mesylate;Methylene blue leuco base mesylate salt;
Formula	C18H27N3O6S3	M. Wt	477.62

Description	TRX-0237 mesylate, also known as LMTX, is a second-generation tau protein aggregation inhibitor for the treatment of Alzheimer's disease (AD) and frontotemporal dementia. It is a replacement formulation for Rember®, the first company's first proprietary formulation of methylthioninium chloride (MTC). Both TRx 0237 and Rember are purified forms of Methylene Blue, an old drug that predates the FDA and is being widely used in Africa for the treatment for malaria, as well as for methemoglobinemia and other conditions. TRx 0237 and Rember share the same mode of action, but TRx 0237 has been designed as a stabilized, reduced form of MTC to improve the drug's absorption, bioavailability, and tolerability.
Pathways	Others Pathway
Targets	Others

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.